Showing results (251-260 of 274) with videos related to

Sort By:
Pageof 28
The American Journal of Sports Medicine|August 19, 2020
Bifactor Model of the Sport Concussion Assessment Tool Symptom Checklist: Replication and Invariance Across Time in the CARE Consortium SampleBenjamin L Brett, Mark D Kramer, Michael A McCrea, et al.
The American Journal of Sports Medicine|May 14, 2024
The Prevalence and Influence of New or Worsened Neck Pain After a Sport-Related Concussion in Collegiate Athletes: A Study From the CARE ConsortiumJeffrey A King, Lindsay D Nelson, Kelly Cheever, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
The American Journal of Sports Medicine|April 17, 2020
Investigating the Range of Symptom Endorsement at Initiation of a Graduated Return-to-Play Protocol After Concussion and Duration of the Protocol: A Study From the National Collegiate Athletic Association-Department of Defense Concussion, Assessment, Research, and Education (CARE) ConsortiumBenjamin L Brett, Katherine Breedlove, Thomas W McAllister, et al.
Pageof 28